Preliminary data suggest that high LIFR expression is associated with worse outcomes in advanced GC, while LIF expression may correlate with improved responsiveness to chemoimmunotherapy and favorable remodeling of the tumor immune microenvironment. Here, LIF is linked to gastric cancer.